NEW YORK (GenomeWeb) – Later this month, London-based DNAe expects to begin validating an integrated prototype of a semiconductor-based sepsis test that could eventually identify pathogens directly from blood within three hours.  

Until recently, the firm has been validating components of the test, but it is now poised to begin running clinical blood samples through the integrated prototype for the first time, DNAe CEO Steve Allen said in an interview.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.